Goldstein, G <br/><br/>
Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.  [electronic resource] 

 -  Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association  Mar 1995 
 - 279-88 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1077-9450 
<br/><br/><label>Standard No.: </label>10.1097/00042560-199503010-00009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>CD4 Lymphocyte Count<br/>Disease Progression<br/>Double-Blind Method<br/>Drug Resistance, Microbial--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>HIV--drug effects<br/>HIV Core Protein p24--blood<br/>HIV Infections--drug therapy<br/>Humans<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged<br/>Patient Compliance<br/>Pentamidine--therapeutic use<br/>Pneumonia, Pneumocystis--prevention & control<br/>Prognosis<br/>Proportional Hazards Models<br/>Thymopentin--administration & dosage<br/>Trimethoprim, Sulfamethoxazole Drug Combination--therapeutic use<br/>Zidovudine--therapeutic use